These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 1309633)
21. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597 [TBL] [Abstract][Full Text] [Related]
22. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597 [TBL] [Abstract][Full Text] [Related]
23. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial. Van den Brande P; De Ruysscher D; Vansteenkiste J; Spaas P; Specenier P; Demedts M Lung Cancer; 1998 Oct; 22(1):45-53. PubMed ID: 9869107 [TBL] [Abstract][Full Text] [Related]
24. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091 [TBL] [Abstract][Full Text] [Related]
25. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Kodani T; Ueoka H; Kiura K; Tabata M; Takigawa N; Segawa Y; Moritaka T; Hiraki S; Harada M; Tanimoto M Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Crinò L; Clerici M; Figoli F; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F; Boni C Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749 [TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054 [TBL] [Abstract][Full Text] [Related]
28. [Combination chemotherapy consisting of ifosfamide and vindesine for non-small cell lung cancer in the elderly]. Takigawa N; Segawa Y; Kishino D; Fujiwara K; Ida M; Eguchi K Nihon Kokyuki Gakkai Zasshi; 2000 Apr; 38(4):273-7. PubMed ID: 10879029 [TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial. Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069 [TBL] [Abstract][Full Text] [Related]
30. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. Murray N; Coppin C; Coldman A; Pater J; Rapp E J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949 [TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075 [TBL] [Abstract][Full Text] [Related]
32. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer. Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174 [TBL] [Abstract][Full Text] [Related]
33. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Ohnoshi T; Hiraki S; Ueda N; Fujii M; Machida K; Ueoka H; Kawahara S; Kozuka A; Kiura K; Moritaka T Acta Med Okayama; 1991 Oct; 45(5):357-61. PubMed ID: 1661559 [TBL] [Abstract][Full Text] [Related]
35. [Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine]. Drings P; Becker H; Bülzebruck H; Djawid N; Ruchalla E; Stiefel P; Tessen HW Onkologie; 1988; 11 Suppl 2():47-56. PubMed ID: 2851761 [TBL] [Abstract][Full Text] [Related]
36. Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study. Honda R; Fujita A; Inoue Y; Asakawa M; Suzuki A Cancer Chemother Pharmacol; 1990; 26(5):373-6. PubMed ID: 2170045 [TBL] [Abstract][Full Text] [Related]
37. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Kawahara M; Furuse K; Kodama N; Yamamoto M; Kubota K; Takada M; Negoro S; Kusunoki Y; Matui K; Takifuji N Cancer; 1991 Aug; 68(4):714-9. PubMed ID: 1649683 [TBL] [Abstract][Full Text] [Related]
38. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin. González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287 [TBL] [Abstract][Full Text] [Related]
39. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. Einhorn LH; Loehrer PJ; Williams SD; Meyers S; Gabrys T; Nattan SR; Woodburn R; Drasga R; Songer J; Fisher W J Clin Oncol; 1986 Jul; 4(7):1037-43. PubMed ID: 3088219 [TBL] [Abstract][Full Text] [Related]
40. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials. Kosmidis P; Mylonakis N; Skarlos DV; Samantas E; Beer M; Theocharis D; Zachariadis E; Gioti A; Papadakis E; Poulakis N Ann Oncol; 1994 Feb; 5(2):159-62. PubMed ID: 8186159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]